• Test code: 04741
  • Turnaround time:
    10–21 calendar days (14 days on average)
  • Preferred specimen:
    3mL whole blood in a purple-top tube
  • Alternate specimens:
    DNA or saliva/assisted saliva
  • Sample requirements
  • Request a sample kit

Invitae Baraitser-Winter Cerebrofrontofacial Syndrome Panel

Test description

The Invitae Baraitser-Winter Cerebrofrontofacial Syndrome Panel analyzes two genes that are associated with Baraitser-Winter cerebrofrontofacial (BWCFF) syndrome, which is characterized by variable brain anomalies ranging from pachygyria through lissencephaly and accompanied by facial features, short stature, congenital heart defects, hearing loss, genitourinary problems, and muscle wasting. Additional features, such as seizures, renal anomalies, and congenital heart defects are also common. These genes were selected based on the available evidence to date to provide Invitae’s broadest test for BWCFF syndrome.

Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant can inform recurrence-risk assessment and genetic counseling.

Order test

Primary panel (2 genes)

Alternative tests to consider

The features exhibited in BWCFF syndrome are similar to and overlap with those present in RASopathies (such as Noonan syndrome). This panel can be ordered with this test at no additional charge.

The features exhibited in BWCFF syndrome are similar to and overlap with those present in Kabuki syndrome. This panel can be ordered with this test at no additional charge.

  • Baraitser-Winter cerebrofrontofacial syndrome

BWCFF syndrome is a heterogeneous syndrome that can present across a spectrum from mild to profound developmental delay and intellectual disability, facial features, coloboma and additional symptoms. The severity of intellectual disability/developmental delay and presence of seizures correlates with the degree to which neuronal migration defects are evident. The most frequent observation is pachygyria; however, some individuals show no obvious defect, while others manifest lissencephaly.

Common facial features include hypoplasia, coloboma of the retina or iris, hypertelorism, ptosis, high-arched brows, broad nasal bridge, long philtrum and pointed chin. Other common features include sensorineural hearing loss, muscle wasting, congenital heart defects and short stature. Additionally, genitourinary/renal problems and contractures have been reported. Expressivity is noted to be highly variable.

Variants in ACTB appear to represent >60% of disease while variants in ACTG1 probably represents about 20%. It is not known if other genes may also cause this disease.

This condition is inherited in an autosomal dominant manner and, to date, most reported variants have been de novo.

This condition is believed to be fully penetrant.

This condition is very rare, with only about 50 individuals confirmed with a diagnosis to date. However, it is thought that this condition is under-recognized, and therefore, the actual prevalence may be significantly higher.

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below. In addition, the analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
ACTB NM_001101.3
ACTG1 NM_001614.3